En español
NIDA

Menu

Publications

Quick Links

Tennessee Opioid Summary

Revised March 2019

Opioid-Related Overdose Deaths

In 2017, there were 1,269 overdose deaths involving opioids in Tennessee—a rate of 19.3 deaths per 100,000 persons, which is higher than the national rate of 14.6 deaths per 100,000 persons.

The greatest increase in opioid deaths was seen in cases involving synthetic opioids (mainly fentanyl): a rise from 77 deaths in 2012 to 590 in 2017. Deaths involving heroin also increased dramatically in the same 5-year period: from 50 to 311 deaths. There were 644 deaths involving prescription opioids in 2017, a decrease from 739 in 2016 (Figure 1).

See textFigure 1. Number of overdose deaths involving opioids in the Tennessee, by opioid category. Source: CDC WONDER.

Opioid Pain Reliever Prescriptions

In 2017, Tennessee providers wrote 94.4 opioid prescriptions for every 100 persons (Figure 2). This was the third highest prescribing rate in the country and 1.5 times greater than the average U.S. rate of 58.7 prescriptions. Still, this represents a 25-percent decline in the state’s opioid prescribing rate since 2013 (CDC). 

The rate of overdose deaths involving opioid prescriptions rose steadily after 1999 to 11.1 deaths per 100,000 persons (Figure 2), but in 2017 it declined to 9.6 deaths per 100,000 persons.

See textFigure 2. Tennessee rate of overdose deaths involving prescriptions opioids and the opioid prescribing rate. Source: CDC and CDC WONDER.

Neonatal Abstinence Syndrome (NAS)

NAS or neonatal opioid withdrawal syndrome (NOWS) may occur when a pregnant woman uses drugs such as opioids during pregnancy. A recent national study showed a fivefold increase in the incidence of NAS/NOWS between 2004 and 2014, from 1.5 cases per 1,000 hospital births to 8.0 cases per 1,000 hospital births. That is one baby born with NAS/NOWS every 15 minutes in the United States. During the same period, hospital costs for NAS/NOW births increased from $91 million to $563 million, after adjusting for inflation (Figure 3).

The Tennessee Department of Health (TDH) requires that all cases of NAS/NOWS be reported within 30 days of diagnosis. In 2017, there were 1,090 cases of NAS/NOWS reported, representing 1.35% of all live births, and a 16 percent increase from 936 cases in 2013. Of the cases reported in the state in 2017, nearly 1 in 3 occurred as a result of exposure to diverted prescription opioid medications (TN Department of Health, 2018).

See textFigure 3. NAS/NOW Incidence Rate and Hospital Costs for Treatment in the United States. Source: T N.A. Winkelman, et al., 2018.

HIV Prevalence and HIV Diagnoses Attributed to Injection Drug Use (IDU)

See textFigure 4. Tennessee: Estimated percent of male vs. female with new HIV diagnoses, by transmission category, 2016. Source: CDC and www.AIDSVU.org.
  • U.S. Incidence: In 2016, 9 percent (3,480) of the 39,589 new diagnoses of HIV in the United States were attributed to IDU. Among new cases, 6.3 percent (2,530) were transmitted via IDU or male-to-male contact and IDU among men, and 2.3 percent (950) were transmitted via IDU among women (CDC).
  • U.S. Prevalence:In 2016, 991,447 Americans were living with a diagnosed HIV infection—a rate of 306.6 cases per 100,000 persons. Among males, 19.9 percent (150,466) contracted HIV from IDU or male-to-male contact and IDU while 21 percent (50,154) of females were living with HIV attributed to IDU (CDC).
  • State Incidence: Of the new HIV cases in 2016, 715 occurred in Tennessee. Among males, 6.6 percent of new HIV cases were attributed to IDU or male-to-male contact and IDU. Among females, 8.1 percent of new HIV cases were attributed to IDU (Figure 4) (AIDSVu).
  • State Prevalence: In 2015, an estimated 16,425 persons were living with a diagnosed HIV infection in Tennessee—a rate of 297 cases per 100,000 persons. Of those, 11 percent of male cases were attributed to IDU or male-to-male contact and IDU. Among females, 13.5 percent were living with HIV attributed to IDU (AIDSVu).

Hepatitis C (HCV) Prevalence and HCV Diagnoses Attributed to Injection Drug Use1

  • U.S. Incidence: In 2016, there were an estimated 41,200 new cases of acute HCV2 (CDC). Among cases reports that contain information about IDU, 68.6 percent indicated use of injection drugs (CDC).
  • U.S. Prevalence: An estimated 2.4 million Americans are living with HCV based on 2013-2016 annual averages (CDC).
  • State Incidence: There were approximately 150 new cases of acute HCV (2.3 per 100,000 persons) reported in Tennessee in 2016 (CDC).
  • State Prevalence: In Tennessee, there are an estimated 69,800 persons living with Hepatitis C (2013-2016 annual average), a rate of 1,380 cases per 100,000 persons (HepVu).

Notes

  1. Not all states collect or report data on the incidence or prevalence of Hepatitis C or on how Hepatitis C is transmitted. When available, the data will be included.
  2. Actual acute cases estimated to be 13.9 times the number of reported cases in any year.

This page was last updated March 2019

Get this Publication

Opioid Summaries by State

NIH HEAL (Helping to End Addiction Long-term) Initiative

New Opioid Overdose Materials for Patients

Easy-to-read Drug Facts

This Is NIDA: Opioids

This Is NIDA: Opioids

The National Institute on Drug Abuse's research-based, informative video series "This Is NIDA," addresses the topic of OPIOIDS.